▲ Peaking
Business
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis expands its therapeutic pipeline through a new global license agreement for a preclinical radioligand asset.
Radioligand
1 trends tracked about this subject — the full history, oldest to newest below.